Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML). Kolitz, J. E., Strickland, S., Cortes, J. E., Hogge, D., Lancet, J. E., Goldberg, S. L., Chung, K. C., Ryan, R., Chiarella, M., Louie, A., Stuart, R. K., Medeiros, B. C. AMER SOC CLINICAL ONCOLOGY. 2017

View details for DOI 10.1200/JCO.2017.35.15_suppl.7036

View details for Web of Science ID 000411931708066